EC adds Cellnovo to R&D project to add artificial intelligence in Type 1 diabetes management

Connected insulin patch pump--Courtesy of Cellnovo

Cellnovo Group ($CLNV) is already part of a major NIH trial for an artificial pancreas that incorporates its connected insulin pump-blood glucose monitor. Now, it's joining a European Commission-sponsored R&D project to develop new technology aimed at Type 1 diabetics.

Dubbed PEPPER (Patient Empowerment through Predictive Personalised decision support), the project is also being conducted with U.K. and European universities for better self-management of the disease. The three-year project is financed with almost €4 million ($4.5 million).

"The Cellnovo diabetes management system is an ideal platform for a personalised decision support system because of its real-time connected data, as well as its wearability and discreetness," said Cellnovo CEO Sophie Baratte in a statement. "The funding by the European Commission's Horizon 2020 programme further demonstrates its key role in this pioneering area of diabetes research."

In the EU, Cellnovo markets an all-in-one insulin patch pump and mobile controller with a blood glucose meter. Project researchers will use the company's diabetes management system to create a personalized decision support system that makes predictions based on real-time data.

The research aims to develop artificial intelligence that, combined with computer modeling, could be integrated into the system. It will also review how human behavior and tech usability issues weigh on chronic disease management.

The system is expected to offer features such as glucose level predictions, dose advice and alarms. It's aimed at preventing hypoglycemic or hyperglycemic episodes, as well as improving patient lifestyle, monitoring and quality of life. It will be integrated with Cellnovo's patch pump.

The project is led by Oxford Brookes University with participation from Imperial College London, University de Girona and the Girona Biomedical Research Institute. It is slated to run until January 2019.

"We believe that better use of data and technology has the power to improve health, transforming the quality and reducing the cost of health and care services," said Clare Martin of Oxford Brookes University. "Cellnovo's innovative technology, empowering diabetes patients to accurately self-manage their condition, fits perfectly with the overall aim of the PEPPER project."

- here is the release
- and here is the PEPPER project description

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.